Pacira Pharmaceuticals (PCRX) PT Lowered to $40 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $36.39 --0%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $50.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Taiwan Semiconductor Manufacturing Co. Ltd. (2330:TT) (TSM) PT Raised to NT$3,828 at Bernstein SocGen Group
- Willis Towers Watson (WTW) PT Raised to $325 at Morgan Stanley
- Waters Corp. (WAT) PT Raised to $500 at KeyBanc
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
